Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Najafi
Safa
S
Medical Oncology and Hematology, Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran. safa3n@icbc.ir
Djavid
Gholamreza Esmaeeli
GE
Mehrdad
Neda
N
Rajaii
Elahe
E
Alavi
Nasrinsadat
N
Olfatbakhsh
Aseih
A
Najafi
Masomeh
M
Bahrami
Alireza
A
Heidari
Kazem
K
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced*; D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D001952:Bridged-Ring Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D011960:Receptors, Estrogen / Q000187:drug effects; D011980:Receptors, Progesterone / Q000187:drug effects; D012189:Retrospective Studies; D012307:Risk Factors; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D018943:Anthracyclines; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids; C080625:taxane; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate